Author:
Park Yoon Soo,Adams-Haduch Jennifer M.,Shutt Kathleen A.,Yarabinec Daniel M.,Johnson Laura E.,Hingwe Ameet,Lewis James S.,Jorgensen James H.,Doi Yohei
Abstract
ABSTRACTWe investigated the clinical and microbiologic features of 300 cases of cephalosporin-resistantEscherichia coliproducing extended-spectrum β-lactamase (ESBL) or plasmid-mediated AmpC β-lactamase (pAmpC) at three medical centers in the United States. Solid-organ malignancy, connective tissue disease, and a recent history of surgery were more common among pAmpC-producing cases (n= 49), whereas urinary catheter at enrollment, diabetes, and hospitalization in the past year were more common among ESBL-producing cases (n= 233). The factors independently associated with clinical outcome were the following: the presence of cardiovascular disease (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.29 to 6.43), intra-abdominal infection (OR, 6.35; 95% CI, 1.51 to 26.7), other or multiples sources of infection (OR, 8.12; 95% CI, 2.3 to 28.6), age of 65 years or greater (OR, 0.43; 95% CI, 0.2 to 0.95), favorable baseline health status (OR, 0.39; 95% CI, 0.16 to 0.95), and appropriate empirical antimicrobial therapy given in the first 72 h (OR, 0.42; 95% CI, 0.20 to 0.88). β-Lactamase genes responsible for cephalosporin resistance were identified in 291 cases. CTX-M-type ESBLs accounted for 72.0%. Of those, 88.0% were CTX-M-15. The next most common type was CMY-type pAmpC (16.7%), followed by SHV- and TEM-type ESBLs (6.3 and 1.3%, respectively). Seven cases (2.3%) had KPC-type β-lactamase. Ertapenem, imipenem, meropenem, doripenem, piperacillin-tazobactam, amikacin, nitrofurantoin, and tigecycline were highly active, with greater than 90% of the isolates being susceptible. Cefepime was less active, with only 74.2% being susceptible due to the predominance of CTX-M-15. These findings have implications in the selection of appropriate empirical therapy when infection due to cephalosporin-resistantE. coliis suspected.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference18 articles.
1. Extended-spectrum β-lactamases in North America, 1987 to 2006;Bush;Clin. Microbiol. Infect,2008
2. Performance standards for antimicrobial susceptibility testing, 19th informational supplement. M100-S19;Clinical and Laboratory Standards Institute,2009
3. Performance standards for antimicrobial susceptibility testing, 20th informational supplement. M100-S20;Clinical and Laboratory Standards Institute,2010
4. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States;Endimiani;Antimicrob. Agents Chemother,2008
5. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections;Friedman;Ann. Intern. Med,2002